湖北广济药业股份有限公司监事会 关于《董事会关于公司 2024 年度带强调事项段的无 保留意见的审计报告的专项说明》的意见 公司聘请利安达会计师事务所（特殊普通合伙）（以下简称"利安达"）对 湖北广济药业股份有限公司（以下简称"广济药业"或"公司"）2024 年度财 务报表进行了审计，出具了带强调事项段的无保留意见的审计报告（报告编号： 利安达审字[2025]第 0435 号）。根据中国证券监督管理委员会《公开发行证券 的公司信息披露编报规则第 14 号——非标准审计意见及其涉及事项的处理》和 《深圳证券交易所股票上市规则》的相关要求，公司董事会出具了《董事会关于 公司 2024 年度带强调事项段的无保留意见的审计报告的专项说明》，现公司监 事会就董事会出具的专项说明发表如下意见： 利安达出具的带强调事项段的无保留意见的审计报告客观、真实地反映了公 司的实际情况，公司监事会对董事会出具的专项说明进行了审核并同意董事会出 具的专项说明。 监事会将积极配合董事会的各项工作，持续关注董事会和管理层相关工作的 开展，以尽快解决报告所涉事项对公司的影响，切实维护公司及全体股东的合法 权益。 湖北广济药业股份有限公司监事 ...

第十一届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：000952 证券简称：广济药业 公告编号：2025-013 湖北广济药业股份有限公司 1、会议通知的时间和方式：会议通知于 2025 年 4 月 14 日以专人送达、书 面传真和电子邮件形式发出； 2、会议的时间和方式：2025 年 4 月 24 日上午 9 点 30 分在湖北广济药业股 份有限公司（以下简称"公司"）武穴市大金产业园行政楼二楼会议室以现场结 合通讯的方式召开； 3、本次会议应到董事 9 人（含独立董事 3 人），实到董事 9 人，胡立刚先 生、龚铖先生、郭韶智先生、方智先生、郭炜先生、洪葵女士、梅建明先生为现 场表决，刘波先生、石守东先生为通讯表决； 表决结果：9 票同意，0 票反对，0 票弃权获得通过。 本议案已经公司第十一届董事会第三次审计委员会审议通过，同意将该议案 提交本次董事会审议。 本议案尚需提交公司 2024 年年度股东会审议。 4、本次会议由董事长胡立刚先生主持，全体监事、高级管理人员列席本次 会议； 5、本次 ...

湖北广济药业股份有限公司（以下简称"广济药业"或"公司"）于 2025 年 4 月 24 日召开第十一届董事会第七次会议和第十一届监事会第六次会议，审议通过了《关于 2024 年度利润分配预案的议案》，本议案尚需提交 2024 年年度股东会审议。现将具体 情况公告如下： 一、本次利润分配方案的基本情况 经利安达会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属于上市公 司股东的净利润为-295,291,149.72 元，提取法定盈余公积金 0 元，加上年初未分配利 润 502,683,090.90 元，合并报表 2024 年度实际可供股东分配的利润为 207,391,941.18 元；母公司 2024 年度实现净利润-34,010,830.77 元，提取法定盈余公积金 0 元，加上 年初未分配利润 927,060,067.64 元，母公司 2024 年度实际可供股东分配的利润为 893,049,236.87 元。 证券代码：000952 证券简称：广济药业 公告编号：2025-016 湖北广济药业股份有限公司 关于 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证信息披露的内容 ...

Financial Performance - The company's operating revenue for 2024 was ¥638,801,583.21, a decrease of 13.42% compared to ¥737,819,479.15 in 2023[20] - The net profit attributable to shareholders for 2024 was -¥295,291,149.72, representing a decline of 110.55% from -¥140,248,068.54 in 2023[20] - The basic earnings per share for 2024 was -¥0.8392, a decline of 111.81% from -¥0.3962 in 2023[20] - The total assets at the end of 2024 were ¥2,793,578,628.65, down 7.79% from ¥3,029,517,090.67 at the end of 2023[20] - The net assets attributable to shareholders decreased by 21.89% to ¥1,064,939,987.31 at the end of 2024, compared to ¥1,363,446,043.29 at the end of 2023[20] - The company reported a significant increase in other business income, which includes technical service fees and rental income, contributing to the overall revenue[20] - The overall economic downturn led to a decline in market demand, resulting in a significant drop in profit levels, with a decrease in joint venture income by CNY 18.99 million and an increase in interest expenses by CNY 12.83 million[37] - The company reported a net profit for 2024 of -¥315.13 million, a decrease of 106.76% compared to -¥152.41 million in 2023, influenced by market supply-demand imbalance and losses from the Jining company[46] Cash Flow and Investments - The net cash flow from operating activities improved to ¥655,357.40 in 2024, a significant increase of 100.44% from -¥148,963,590.35 in 2023[20] - The company received government subsidies amounting to ¥14,403,171.46 in 2024, compared to ¥7,079,147.99 in 2023, reflecting an increase in support[26] - The company achieved a net cash flow from operating activities of ¥0.66 million in 2024, a significant improvement from -¥148.96 million in 2023, due to better management of accounts receivable[45] - Investment activities saw a net cash outflow of -152,775,281.03, a reduction of 73.00% compared to the previous year[67] - The company reported a significant decrease in financing cash inflow by 40.56% to 768,306,480.00, impacting overall cash flow[67] Market and Product Development - The company is a major supplier of Vitamin B2 products globally and has expanded its product line through the acquisition of Shandong Baisheng assets in 2023[31] - The company is focusing on technological innovation and aims to transition from a manufacturing-oriented to an innovation-driven model[32] - The company is currently optimizing its production processes for new products, including VC sodium and lactic acid series products[31] - The vitamin market is facing oversupply issues, leading to increased competition and price fluctuations[31] - The company achieved a 37.32% increase in overseas revenue, reaching ¥250.10 million, while domestic revenue fell by 30.05% to ¥388.70 million[52] - The production volume in the pharmaceutical manufacturing sector (excluding Jining Company) increased by 40.28% to 3,589.98 tons, while sales volume rose by 5.28% to 3,176.64 tons[55] - The company successfully registered sodium riboflavin phosphate in the EU market, marking a significant achievement in international market expansion[49] Research and Development - The company completed 45 patent applications in 2024, including 26 invention patents and 19 utility model patents, with a total of 161 domestic and international patents authorized by the end of the reporting period[41] - Research and development expenses decreased by 23.99% to ¥56.82 million in 2024 from ¥74.75 million in 2023, reflecting reduced investment in R&D projects[45] - The company plans to enhance its product structure and competitiveness through various ongoing R&D projects, including the development of new formulations[64] - The company is focused on attracting high-quality young talent to strengthen its R&D capabilities for future growth[66] Governance and Management - The company maintains a fully independent business operation, with no reliance on the controlling shareholder for procurement, production, or sales[101] - The company has established an independent financial department with a complete accounting system, ensuring no interference from shareholders in financial matters[102] - The company has a governance structure that complies with legal regulations, with no significant discrepancies noted in its governance practices[100] - The management team includes professionals with backgrounds in finance, engineering, and pharmaceuticals, enhancing the company's operational capabilities[113][114] - The company has a structured remuneration plan for directors and senior management, ensuring compliance with relevant regulations[116] Environmental Compliance - The company obtained a pollution discharge permit from Huanggang Ecological Environment Bureau in December 2020, valid until December 28, 2025[152] - The company received a pollution discharge permit from Jining Ecological Environment Bureau in September 2023, valid until September 19, 2028[153] - The main pollutant discharged by Hubei Guangji Pharmaceutical is COD, with a discharge concentration of 139.39 mg/L, below the industry standard of 500 mg/L[153] - The company complies with multiple national and local environmental standards for wastewater and air pollutants[151] - The company has implemented measures to ensure that all emissions are within regulatory limits, demonstrating commitment to environmental compliance[154] Employee and Community Engagement - The total number of employees at the end of the reporting period is 1,398, with 90 in the parent company and 1,308 in major subsidiaries[128] - The company emphasizes human resource development and has established a comprehensive training system to enhance employee skills and knowledge[130] - The company established a regular education support mechanism, investing 10,000 yuan in educational initiatives to aid local schools as part of its social responsibility efforts[168] - The company provided over 30 employment positions in surrounding villages, addressing employment challenges for vulnerable groups[168] Future Outlook - The company aims to enhance its market presence and operational efficiency through these management changes and strategic appointments[110] - Future strategies include enhancing wastewater treatment processes to further minimize discharge levels[154] - The company is actively pursuing market expansion strategies, particularly in international markets, to drive revenue growth[108] - The overall performance guidance for the upcoming fiscal year suggests a positive growth trajectory, supported by strategic initiatives and management restructuring[110]

Financial Performance - The company's operating revenue for Q1 2025 was ¥148,487,959.52, a decrease of 17.58% compared to ¥180,161,008.71 in the same period last year[5] - The net loss attributable to shareholders was ¥36,266,158.34, an improvement of 28.20% from a loss of ¥50,508,221.70 in the previous year[5] - The company reported a significant decrease in operating costs, which fell by 29.98% to ¥105,498,174.52, mainly due to lower sales volumes[10] - Net profit for the period was a loss of ¥40,179,691.10, compared to a loss of ¥54,669,434.50 in the previous period, indicating an improvement of approximately 26.5%[22] - The total comprehensive income for the period was -40,179,608.36 yuan, compared to -54,673,971.69 yuan in the previous period[23] - Basic and diluted earnings per share were both -0.1037 yuan, an improvement from -0.1427 yuan in the previous period[23] Cash Flow - The net cash flow from operating activities improved significantly to -¥584,644.24, a 98.79% increase compared to -¥48,243,051.48 in the same period last year[5] - Cash inflow from operating activities totaled 164,176,256.62 yuan, down from 281,576,516.95 yuan in the previous period[24] - Cash outflow from operating activities was 164,760,900.86 yuan, compared to 329,819,568.43 yuan in the previous period[25] - Net cash flow from investing activities was 37,259,004.87 yuan, compared to -26,527,939.59 yuan in the previous period[25] - Net cash flow from financing activities was 78,102,421.74 yuan, an increase from 62,815,258.68 yuan in the previous period[25] - The ending cash and cash equivalents balance was 422,361,332.62 yuan, up from 403,741,511.20 yuan in the previous period[25] Assets and Liabilities - Total assets increased by 3.57% to ¥2,893,357,332.63 from ¥2,793,578,628.65 at the end of the previous year[5] - Current liabilities rose to ¥1,133,129,466.25 from ¥927,514,498.99, an increase of approximately 22.2%[19] - Non-current liabilities decreased to ¥723,975,555.91 from ¥789,867,879.44, a decline of about 8.4%[19] - The company's total equity attributable to shareholders decreased by 3.39% to ¥1,028,882,808.00 from ¥1,064,939,987.31 at the end of the previous year[5] - The company's total equity decreased to ¥1,036,252,310.47 from ¥1,076,196,250.22, a decrease of approximately 3.7%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,038, with no preferred shareholders having restored voting rights[13] - The largest shareholder, Changjiang Industrial Investment Group, holds 25.04% of shares, totaling 87,592,065 shares[13] - The company has no preferred shareholders and no significant changes in the top ten shareholders' participation in margin trading[14] - The company has not identified any related party relationships among the top ten shareholders, except for Changjiang Industrial Investment Group[13] - The company did not undergo an audit for the first quarter report[26] Capital and Investment - The company plans to raise capital through public listing for its wholly-owned subsidiary, Hubei Guanghua Pharmaceutical Co., Ltd., with a new registered capital of RMB 250 million[14] - Two strategic investors have been identified for the capital increase, with investments of RMB 200 million and RMB 50 million respectively[15] - The company has not utilized its preemptive rights in the capital increase process for its subsidiary[14] - The company will no longer consolidate Hubei Guanghua Pharmaceutical into its financial statements after the capital increase[14] Research and Development - Research and development expenses decreased by 32.22% to ¥10,910,609.64, attributed to reduced investment in R&D projects during the reporting period[10] - Research and development expenses decreased to ¥10,910,609.64 from ¥16,095,943.13, a reduction of about 32.3% year-over-year[22] Other Financial Metrics - Cash and cash equivalents rose by 37.50% to ¥422,361,332.62, primarily due to increased cash flow from investment and operating activities[8] - The company reported a significant increase in other payables, rising to ¥137,256,241.36 from ¥80,524,801.45, an increase of approximately 70.3%[19] - Accounts receivable decreased to RMB 168,273,997.44 from RMB 174,029,671.89[17]

湖北广济药业股份有限公司 章 程 （2025年4月） | 第一章 | 总则 4 | | --- | --- | | 第二章 | 经营宗旨和范围 5 | | 第三章 | 股份 5 | | | 第一节 股份发行 5 | | | 第二节 股份增减和回购 6 | | | 第三节 股份转让 7 | | 第四章 | 股东和股东会 7 | | | 第一节 股东 8 | | | 第二节 股东会的一般规定 10 | | | 第三节 股东会的召集 12 | | | 第四节 股东会的提案与通知 13 | | | 第五节 股东会的召开 15 | | | 第六节 股东会的表决和决议 18 | | 第五章 | 公司党委 21 | | 第六章 | 董事会 23 | | | 第一节 董事 23 | | | 第二节 董事会 26 | | 第七章 | 经理及其他高级管理人员 31 | | 第八章 | 监事会 32 | | | 第一节 监事 32 | | | 第二节 监事会 33 | | 第九章 | 财务会计制度、利润分配和审计 34 | | | 第一节 财务会计制度 34 | | | 第二节 内部审计 37 | | | 第三节 会计师事务所的聘 ...

一、会议召开和出席情况 1、会议召开的情况 （1）会议召开时间 证券代码：000952 证券简称：广济药业 公告编号：2025-012 湖北广济药业股份有限公司 2025 年第一次临时股东会决议公告 误 导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决提案的事项。 2、本次股东会不涉及变更以往股东会已通过的决议。 现场会议时间：2025 年 4 月 10 日（星期四）下午 15:30 网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 4 月 10 日上午 9:15-9:25，9:30-11:30 和下午 13:00-15:00； ②通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 4 月 10 日上午 9:15 至下午 15:00 期间的任意时间。 （2）现场会议召开地点：湖北省武穴市大金镇梅武路 100 号大金产业园行 政楼二楼会议室。 （3）召开方式：本次股东会采取现场投票与网络投票相结合的方式召开。 （4）召集人：湖北广济药业股份有限公司（以下简称"公司"）董事会。 （5）主持人：董事长胡立刚先生。 （6）本次股东会的召集与召开程序、出席会议人员 ...

湖北众勤律师事务所 关于湖北广济药业股份有限公司 2025年第一次临时股东会的 法律意见书 武汉市洪山区徐东大街 79 号中兴时代数贸港 A 栋 20 层 邮编：430070 电话：027-88871993 网址：www.zhongqinlawyer.cn 关于湖北广济药业股份有限公司 2025 年第一次临时股东会的法律意见书 湖北众勤律师事务所 关于湖北广济药业股份有限公司 2025 年第一次临时股东会的 法律意见书 众勤（2025）顾字第056-19号 致：湖北广济药业股份有限公司 受湖北广济药业股份有限公司的委托，湖北众勤律师事务所指派本所律师出 席了公司于2025年4月10日召开的2025年第一次临时股东会（以下简称"本次股 东会"）。现根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会 发布的《上市公司股东会规则》以及《深圳证券交易所上市公司自律监管指引第 1号——主板上市公司规范运作》等相关法律、行政法规、规范性文件以及《湖 北广济药业股份有限公司章程》（以下简称"《公司章程》"）的规定，对本次 股东会的召集、召开程 ...

证券代码：000952 证券简称：广济药业 公告编号：2025-010 湖北广济药业股份有限公司 关于全资子公司湖北广化制药有限公司公开挂牌增资 并放弃优先认购权暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 2、公司在本次增资扩股中放弃优先认缴权。本次增资扩股完成后，广化制 药注册资本将变更为 35,000 万元，其中长江医疗持有广化制药 57.14%股权，黄 冈高投持有广化制药 14.29%股权，公司持有广化制药 28.57%股权，广化制药不 再纳入公司合并报表范围。 3、本次增资扩股事项不构成《上市公司重大资产重组管理办法》规定的重 大资产重组。 4、根据《深圳证券交易所股票上市规则》的相关规定，长江医疗为公司控 股股东长江产业投资集团有限公司全资子公司，与公司存在关联关系，本次交易 事项构成关联交易。本次交易尚需提交公司股东会审议。 一、关联交易概述 1、交易情况 2024 年 12 月 27 日，公司召开第十一届董事会第四次（临时）会议、第十 一届监事会第三次（临时）会议，审议通过了《关于全资子公司湖北广化制药有 限公司 ...

证券代码：000952 证券简称：广济药业 公告编号：2025-011 湖北广济药业股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 湖北广济药业股份有限公司（以下简称"公司"或"广济药业"）于 2025 年 3 月 21 日召开的第十一届董事会第六次（临时）会议审议通过了《关于召开 2025 年第一次临时股东会的议案》，同意召开本次股东会，现将有关事项通知 如下： 一、召开会议的基本情况 1、股东会届次：广济药业 2025 年第一次临时股东会 2、召集人：公司董事会，经公司第十一届董事会第六次（临时）会议审 议，决定召开公司 2025 年第一次临时股东会。 3、会议召开的合法、合规性：公司董事会认为本次股东会的召开符合有关 法律、行政法规、部门规章、规范性文件、深圳证券交易所业务规则和《公司 章程》的规定。 4、会议召开的日期和时间： （1）现场会议召开日期和时间：2025 年 4 月 10 日（星期四）下午 15:30 （2）网络投票时间：2025 年 4 月 10 日（星期四） 其中，通过深圳证券 ...